
|Articles|September 23, 2021
Pharmacy Clinical Pearl of the Day: Amyotrophic Lateral Sclerosis
Author(s)Saro Arakelians, PharmD
ALS results in muscles that are reduced in size (atrophic), weak, and soft, or muscles that are stiff, tight, and spastic.
Advertisement
Clinical Pearl of the Day: Amyotrophic lateral sclerosis (ALS) disease
ALS is a disease that impacts the parts of the nervous system that control voluntary muscle movement.
Explanation:
- ALS is the most common form of motor neuron disease.
- As these motor neurons are lost, the muscles they control become weak and then nonfunctional, thus leading to muscle weakness, disability, and eventually death.
- ALS usually strikes in late middle age (the late 50s is average) or later.
- ALS results in muscles that are reduced in size (atrophic), weak, and soft, or muscles that are stiff, tight, and spastic.
- Treatment options may include medications such as Rilutek, Radicava, breathing care, physical therapy, occupational therapy, speech therapy, nutitional and psychosocial therapy.
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
GLP-1 Receptor Agonists Show Promise Across Alcohol, Opioid, and Tobacco Use Disorders
2
UConn’s Medical Writing Certificate Program: It’s Just "Write"
3
Pharmacy Policy Updates for October 2025
4
TACTI-004 Trial Studying Eftilagimod Alfa With Pembrolizumab in Advanced NSCLC to Begin Evaluation
5